Literature DB >> 14978254

Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms.

Martin Beinborn1, Yong Ren, Michael Bläker, Ci Chen, Alan S Kopin.   

Abstract

It has been proposed that mutations that induce constitutive activity in G-protein-coupled receptors (GPCRs) concomitantly enhance the ability of partial agonists to trigger second-messenger signaling. Using the cholecystokinin type 2 receptor (CCK-2R) as a model system, we have explored whether this association applies to a diverse set of activating mutations. Consistent with established principles, constitutively active CCK-2Rs resulting from amino acid substitutions within the third intracellular loop each systematically increased partial agonist activities versus corresponding wild-type values. In contrast, activating mutations within transmembrane domain segments near the extracellular loops led to an increase in efficacy of only a subset of compounds but decreased or did not change the function of others. When transmembrane domain amino acid substitutions were introduced in combination with intracellular amplifying mutations, observed changes in ligand activity were defined by the product of two discernible factors 1) systematic amplification caused by an equilibrium shift from the inactive to the active receptor conformation and 2) ligand-specific alterations in signaling, which probably result from mutation-induced changes in the putative binding pocket. These findings illustrate functional heterogeneity among GPCR mutants with ligand-independent signaling. A subgroup of activating mutations facilitates receptor isomerization to the active state and in parallel perturbs ligand receptor interactions. These mutants do not adhere to the previously proposed "hallmark criteria" of constitutive activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978254     DOI: 10.1124/mol.65.3.753

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Naturally occurring HCA1 missense mutations result in loss of function: potential impact on lipid deposition.

Authors:  Jamie R Doyle; Jacqueline M Lane; Martin Beinborn; Alan S Kopin
Journal:  J Lipid Res       Date:  2012-12-24       Impact factor: 5.922

2.  The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.

Authors:  Jean-Philippe Fortin; Lei Ci; Jonathan Schroeder; Carmit Goldstein; Maria Claudia Montefusco; Inga Peter; Steven E Reis; Gordon S Huggins; Martin Beinborn; Alan S Kopin
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

3.  Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways.

Authors:  J R Doyle; J P Fortin; M Beinborn; A S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2012-04-30       Impact factor: 4.030

4.  Pharmacological characterization of human incretin receptor missense variants.

Authors:  Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

5.  Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants.

Authors:  Munya A Al-Fulaij; Yong Ren; Martin Beinborn; Alan S Kopin
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

Review 6.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

7.  Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation.

Authors:  E Charmandari; R Guan; M Zhang; L G Silveira; Q R Fan; G P Chrousos; A C Sertedaki; A C Latronico; D L Segaloff
Journal:  Mol Endocrinol       Date:  2015-11-10

8.  Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.

Authors:  Alex de Voux; Mei-Chi Chan; Asongna T Folefoc; Michael T Madziva; Colleen A Flanagan
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.